Table 1.
Comparison of demographic features of MPH and ATX-treated groups
| MPH (n=35) | ATX (n=9) | p-value | |
|---|---|---|---|
| Age (mean±SD, yr) | 19.54±4.00 | 17.78±2.68 | 0.219 |
| Duration of illness (mean±SD, yr) | 4.40±3.93 | 4.11±2.98 | 0.838 |
| Sex | |||
| Male | 26 | 8 | 0.657 |
| Female | 9 | 1 | |
| Full scale IQ (mean±SD) | 94.42±15.82 | 95.29±11.47 | 0.892 |
| Dose (mean±SD, mg) | 45.79±21.99 | 71.78±23.82 | |
| Cormorbid diagnosis (%) | |||
| Depressive disorder | 21 (60) | 3 (33) | 0.334 |
| Anxiety disorder | 2 (6) | 3 (33) | 0.028 |
| Obsessive compulsive disorder | 2 (6) | 0 | |
| Tic disorder | 0 | 2 (22) | |
| Conduct disorder | 1 (3) | 0 | |
| Bipolar disorder | 1 (3) | 0 | |
| Schizophrenia | 1 (3) | 0 | |
| Concommitant antidepressants (%) | |||
| Escitalopram (5-30 mg) | 18 (51) | 5 (56) | 0.879 |
| Fluoxetine (20 mg) | 1 (3) | 0 | |
| Brintellix (10-20 mg) | 1 (3) | 1 (11) | |
| Bupropion (300 mg) | 1 (3) | 0 | |
| Concommitant antipsychotics (%) | |||
| Risperidone (1-5 mg) | 2 (6) | 2 (22) | 0.143 |
| Olanzapine (20 mg) | 1 (3) | 0 | |
| Aripiprazole (5-25 mg) | 3 (9) | 2 (22) |
SD: standard deviation, MPH: methylphenidate, ATX: atomoxetine, IQ: intelligence quotient